Lexicon Pharmaceuticals, Inc.
|Company Name||Lexicon Pharmaceuticals, Inc.|
On February 28, 2022, Lexicon issued a press release announcing the voluntary withdrawal of the Company’s New Drug Application for its glucose regulation drug, sotagliflozin, in order to correct a technical issue with the submission that had been recently identified by the Company.
On this news, Lexicon’s stock price fell $0.78, or 27.37%, to close at $2.07 per share on February 28, 2022, thereby injuring investors.
Submit Your Information
If you suffered a loss on your Lexicon Pharmaceuticals, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.